Health
Medicine, public health and what new studies mean for patients.
1 story
-
FDA orders a rare optic-nerve warning on every GLP-1 drug, 17 months after Europe did it for semaglutide
The FDA's 9 November safety notice adds NAION to the warnings of all GLP-1 drugs. The trial data is thin: 15 probable events. Europe's regulator reached a similar view for semaglutide in 2025.